Correlation Between Arch Biopartners and NervGen Pharma

Can any of the company-specific risk be diversified away by investing in both Arch Biopartners and NervGen Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Arch Biopartners and NervGen Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Arch Biopartners and NervGen Pharma Corp, you can compare the effects of market volatilities on Arch Biopartners and NervGen Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Arch Biopartners with a short position of NervGen Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Arch Biopartners and NervGen Pharma.

Diversification Opportunities for Arch Biopartners and NervGen Pharma

-0.2

Correlation Coefficient

Arch Biopartners  NervGen Pharma

Good diversification

The 3 months correlation between Arch and NervGen is -0.2. Overlapping area represents the amount of risk that can be diversified away by holding Arch Biopartners and NervGen Pharma Corp in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on NervGen Pharma Corp and Arch Biopartners is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Arch Biopartners are associated (or correlated) with NervGen Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of NervGen Pharma Corp has no effect on the direction of Arch Biopartners i.e., Arch Biopartners and NervGen Pharma go up and down completely randomly.

Pair Corralation between Arch Biopartners and NervGen Pharma

Assuming the 90 days trading horizon Arch Biopartners is expected to under-perform the NervGen Pharma. But the stock apears to be less risky and, when comparing its historical volatility, Arch Biopartners is 3.58 times less risky than NervGen Pharma. The stock trades about -0.21 of its potential returns per unit of risk. The NervGen Pharma Corp is currently generating about 0.11 of returns per unit of risk over similar time horizon. If you would invest  268.00  in NervGen Pharma Corp on September 24, 2024 and sell it today you would earn a total of  32.00  from holding NervGen Pharma Corp or generate 11.94% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Arch Biopartners  vs.  NervGen Pharma Corp

Arch Biopartners

Risk-Adjusted Performance

3 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Arch Biopartners are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal fundamental indicators, Arch Biopartners may actually be approaching a critical reversion point that can send shares even higher in January 2025.

NervGen Pharma Corp

Risk-Adjusted Performance

5 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in NervGen Pharma Corp are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of fairly fragile technical and fundamental indicators, NervGen Pharma showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Arch Biopartners and NervGen Pharma

The main advantage of trading using opposite Arch Biopartners and NervGen Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Arch Biopartners position performs unexpectedly, NervGen Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NervGen Pharma will offset losses from the drop in NervGen Pharma's long position.

The idea behind Arch Biopartners and NervGen Pharma Corp pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.